Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARRY-142886, MEK inhibitor · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ARRY-142886 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ARRY-142886, MEK inhibitor; oral | DRUG | Part 1: single dose and multiple dose, escalating; Part 2: multiple dose, single schedule |
Key Inclusion Criteria (Part 2): * Histopathologically or cytologically confirmed solid tumor that is refractory to standard therapies, or for which no standard therapies exist, or for which the Investigator feels no other active therapy is required for the duration of the study. * Eastern Cooperat...
Top 2 of 3 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
ARRY-142886 is an investigational oral small molecule being studied in advanced cancer. It was evaluated in a Phase 1 trial in patients with advanced cancer. It is not an approved therapy and remains in clinical development.
ARRY-142886 is a MEK inhibitor. It targets MEK, a kinase in the MAPK signaling pathway. By inhibiting MEK, the drug aims to block signals that drive cancer cell growth. This mechanism is being explored in advanced cancer.
Pfizer, Inc. (ticker: PFE) is the developer of ARRY-142886. The company is responsible for its clinical development in advanced cancer.
ARRY-142886 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA for any indication. The Phase 1 program has been completed.
ARRY-142886 was studied in a Phase 1 trial, NCT00085787, titled "A Study of ARRY-142886 in Patients With Advanced Cancer." The trial enrolled 57 patients in the United States and is completed. No active trials are ongoing.
ARRY-142886 is also known as a MEK inhibitor, which describes its drug class. It is an oral small molecule. The names ARRY-142886 and MEK inhibitor refer to the same investigational agent.